Vanda Pharmaceuticals Stock
Vanda Pharmaceuticals Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Mihael H. Polymeropoulos
- Employees
- 533
- Market cap
- $244 M
- IPO
- 12/04/2006
Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions that address critical unmet medical needs. The company currently offers two approved treatments: HETLIOZ, prescribed for non-24-hour sleep-wake disorders, and Fanapt oral tablets, used in the…
Vanda Pharmaceuticals stock: price history
1D
-5.0%
1W
-11.8%
1M
-19.4%
6M
-44.6%
YTD
-54.3%
1Y
-23.5%
2Y
-17.8%
5Y
-78.1%
10Y
-75.0%
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~0% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 13/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Vanda Pharmaceuticals
Analyst assessment of Vanda Pharmaceuticals
PRICE TARGET LOW
US$10.00
CONSENSUS
US$15.50
MEDIAN
US$15.50
PRICE TARGET HIGH
US$21.00
0
STRONG BUY
13
BUY
5
HOLD
1
SELL
0
STRONG SELL
19
TOTAL · Buy
As of: 05/10/2026
Vanda Pharmaceuticals stock metrics
P/E
-0.87
P/B
1.1
EV/EBITDA
-1.28
RETURN ON EQUITY
-28.4%
NET MARGIN
-123.7%
DEBT/EQUITY
0.1
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
94.6%
FLOAT SHARES
57,198,923
AVG. DAILY VOLUME (30D)
1,023,966
Insider transactions (SEC)
Mitchell Stephen Ray
Honore Tage
Ward Anne Sempowski
DUGAN RICHARD W
Duncan Charles Cliff
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -5.0%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Vanda Pharmaceuticals stock
What does Vanda Pharmaceuticals do?
Vanda Pharmaceuticals Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Mihael H. Polymeropoulos, the company employs around 533 people.
The IPO was on 12/04/2006; the stock trades on NASDAQ under the ticker VNDA.
What do analysts say about Vanda Pharmaceuticals stock?
19 analysts rate the stock, the consensus is Buy (as of 05/10/2026).
The average price target is US$15.50, ranging from US$10.00 to US$21.00, with a median of US$15.50.
This is an external assessment, not a statement by Market Jury.
When does Vanda Pharmaceuticals report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly 0% stronger than usual.
Does Vanda Pharmaceuticals pay a dividend?
No, Vanda Pharmaceuticals currently does not pay a dividend.
Which stocks are comparable to Vanda Pharmaceuticals?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Vanda Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess Vanda Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.